The aim of the study. The present report is an attempt at answering the question regarding the ocular status in the course of thyroid ophthalmopathy following surgical treatment. A retrospective analysis included a group of patients presenting with various ophthalmologic symptoms in the course of Graves' disease. The analysis focused on the clinical ophthalmologic status determined based on eye examinations and determinations of the level of thyroid stimulating hormone receptor antibody (TRAb), as well as on changes in the above parameters in pre and postoperative examinations. Material and methods. Between January 2005 and December 2006, 61 patients were managed surgically for Graves' disease. The group consisted of 53 (86.9%) females and eight (13.1%) males. Their mean age was 45.5±12 years, with the range of 18 to 71 years. Prior to surgery, the mean duration of pharmacotherapy was 27.3 months, with the range of 3-120 months. The severity of the disease was determined using the NOSPECS classification and the resultant ophthalmopathy index according to Donaldson. Ocular symptoms were assessed prior to treatment and subsequently at 3, 6 and 12 months after thyroidectomy. Determinations of TSH, fT4 and antithyroid antibodies TRAb were done in all the patients before and 12 months after surgical treatment. In the present investigations, determinations of the thyroid stimulating hormone receptor antibody (TRAb) levels were done by radioimmunoassay. Results. All the 61 patients were treated surgically. The following procedures were performed: total thyroidectomies in 35 (57.4%) patients, the so-called Dunhill operations (total lobectomy plus subtotal resection of the contralateral side) in 14 (23%), and subtotal bilateral lobectomies in 12 (19.6%) subjects. Determinations of thyroid stimulating hormone receptor antibody TRAb levels were done preoperatively in 61 (100%) patients and postoperatively in 54 (88.5%) individuals. In the present series, preoperative TRAb values were significantly elevated (>2 IU/L) in as many as 56 (91.8%) patients. After the surgery, TRAb normalized in 35 (57.4%) patients (<1 IU/L -absent) from 9.14±10.7 to 0.95±0.45 IU/L (p<0.001, test t). The differences are statistically significant. Borderline antibody values (between 1 and 2 IU/l) were noted in 5 (8.1%) patients before and in 18 (29.5%) after the procedure. The ophthalmologic assessment based on the Donaldson ophthalmopathy index, which combines scores awarded while evaluating five classes (soft tissues, degree of exophthalmus, oculomotor muscle status, corneal status, visual acuity) included 54 (88.5%) of 61 patients. The value of the index changed in the entire investigated group, what was manifested in a statistically significant decrease in the ophthalmopathy index from 6.1±2.32 prior to treatment to 3.31±2.09 after the surgery (p<0.001, test t). Deterioration of the general ocular status as confirmed by the initial ophthalmopathy index was confirmed by ophthalmology in five patients. Subjective complaints of deteriorated vision were reported by three patients Conclusions. The use of ultrasonic scalpel in thyroid surgery a reduction of mean operating time, achieving good hemostasis and improved cosmetic results without increased risk of morbidity Key words: thyroid ophtalmopathy, Graves' disease Autoimmune thyroid diseases are the consequence of interactions between genetic, environmental and intrathyroid factors. Many of these constituents have been well investigated and recognized as factors determining disturbances of one or many immune response me-
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A. Konturek et al. total and subtotal bilateral thyroid lobectomies performed by an experienced surgeon in a specialized center, poses a minimal risk of postoperative complication development (7, 8) . Nevertheless, recently, the number of surgical procedures has been decreased in favor of radioactive iodine therapy. The objective of this therapeutic modality is to destroy such a volume of thyroid gland tissue that the therapeutic effect be ablative rather than destructive. A negative consequence of 131 I therapy is a high percentage of hypothyroidism. According to multicenter data, hypothyroidism affects at least one half of patients, occurring shortly after isotope treatment. The condition manifests a tendency to increase in frequency with the increasing time lapse since isotope administration, accounting for 2-3% of new hypothyroidism cases per year (9, 10, 11) .
The above facts prompt raising some questions as to the effect exerted by the pathological thyroid gland on the development of ocular lesions. How are we to assess whether the patient requires aggressive treatment? How to monitor his ophthalmologic status? What agents may be offered to patients who do not require radical treatment? How to modify the treatment of the thyroid disease itself in view of ocular conditions?
The present report is an attempt at answering the question regarding the ocular status in the course of thyroid ophthalmopathy following surgical treatment. A retrospective analysis included a group of patients presenting with various ophthalmologic symptoms in the course of Graves' disease. The analysis focused on the clinical ophthalmologic status determined based on eye examinations and determinations of the level of thyroid stimulating hormone receptor antibody (TRAb), as well as on changes in the above parameters in pre and postoperative examinations. The investigations were carried out in a group of selected patients treated in a single clinical center.
MATERIAL AND METHODS
Between January 2005 and December 2006, 61 patients were managed surgically for Graves' disease. The group consisted of 53 (86.9%) females and eight (13.1%) males. Their mean age was 45.5±12 years, with the range of 18 to 71 years. Prior to surgery, the mean duration of pharmacotherapy was 27.3 months, with the chanisms. Thus, the occurrence of various clinical signs of thyroid disease is the result of a synergy between the above dependences (1). Based on the results of studies carried out in monozygotic twins, it has been established that the effect of genetic factors in some thyroid diseases is as high as as 80%, while the remaining, the so-called environmental factors account for less than 20% (2) . Among diseases with the above background is Graves' disease, referred to as "diffuse toxic goiter". The mechanism behind the disease is an autoimmune reaction leading to production of antithyroid autoantibodies associated with hyperthyroidism. The pathology involving the thyroid gland itself is also accompanied by non-thyroid-related symptoms, which most frequently include lesions of the eye, also called Graves' ophthalmopathy.
Ocular symptoms not only coexist with the afore-mentioned disease, but they may also appear in another pathology with autoimmune background, i.e. Hashimoto's disease. It has been demonstrated that only in some patients these symptoms pose a significant clinical problem and although sight-threatening lesions are relatively rare, intensive subjectively perceived symptoms and a sense of poor facial appearance are an important issue for many individuals. Clinical symptoms are the consequence of an increased volume of orbital tissue and may be easily explained in mechanical terms as an increase of extraorbital tissue (in 46%, the extraocular muscle and extraocular fat, in 46%, muscles alone, and fat alone in 8% only) (3). The increased tissue volume leads to an increase of extraocular pressure due to the confined bony structure of the orbit (4) .
Patients report with their complaints associated with ocular symptoms to endocrinologists, ophthalmologists, specialists in internal diseases, and sometimes to neurologists. Indeed, the management of patients with ophthalmopathy requires collaboration of various specialists, while the basic treatment modalitiesimmunosupression, radiotherapy and surgery -should be employed by specialized centers (5, 6) .
For many years now, surgical treatment of hyperthyroidism has been recognized as a commonly accepted and effective therapeutic modality, which allows for achieving a high percentage of permanent cures within a short time. The scope of procedures, which includes 457 Total thyroidectomy in treatment of Graves' ophthalmopathy range of 3-120 months. All the patients presenting with symptoms of Graves' disease and concomitant ocular symptoms of varying intensity, who were qualified for surgical treatment, were treated conservatively employing thyreostatic drugs, beta-blockers and steroids administered in generally accepted dosage, while closely monitoring their clinical state and lab results (tab. 1). In addition, 14 days prior to the planned surgical procedure, all the Graves' disease patients received 5% Lugol's iodine in two divided doses of 10 drops each, the total dosage being 20 drops per day. All the above preparatory procedures were aimed at achieving clinical and biochemical euthyreosis, and constituted a generally accepted standard of preoperative management.
Indications for surgery included: large goiters presenting with compression symptoms, especially when situated retrosternally and mediastinally, recurrent hyperthyroidism following thyreostatic therapy (surgery in patients in the euthyreotic state), severe and moderate orbitopathy with concomitant thyroid enlargement, cosmetic considerations (such as increased neck circumference). It should be emphasized that indications for surgery might have been represented by two or more factors for a given patient. As it follows from the presented list, the predominant indication for surgery was thyroid enlargement coexisting with various degrees of clinical thyroid orbitopathy (tab. 2).
In view of their ocular symptoms consisting in palpebral and conjunctival infiltration and edema, impaired eyeball mobility with double vision, decreased visual acuity or exophthalmus with the eyeballs protruding beyond the bony margins of the orbit, leading to possible corneal damage due to blepharodiastasis, all the patients were subjected to ophthalmologic examinations and assessment. Examinations aiming at evaluating the degree of ocular symptoms included assessment of lid retraction, status of the soft tissue around the eye, oculomotor muscle mobility, degree of corneal and lenticular transparency and visual acuity, as well as measurements of exophthalmus using the Hertl's exophthalmometer. The severity of the disease was determined using the NOSPECS classification and the resultant ophthalmopathy index according to Donaldson (tab. 3). Ocular symptoms were assessed prior to treatment and subsequently at 3, 6 and 12 months after thyroidectomy.
Determinations of TSH, fT4 and antithyroid antibodies TRAb were done in all the patients before and 12 months after surgical treatment. In the present investigations, determinations of the thyroid stimulating hormone receptor antibody (TRAb) levels were done by radioimmunoassay. Following the manufactu- Table 1 . Preoperative management of patients with Graves's disease and ocular symptoms
Treatment
Number of patients Antithyroid medications (thiamazole, propylthiouracil) + beta-blocker (propranolol) 50 (82%) Antithyroid medications (thiamazole, propylthiouracil) + steroids (methylprednisolone) + beta-blocker (propranolol) 7 (11,5%) Antithyroid medications (thiamazole, propylthiouracil) 4 (6,5%) 1, 2, 3 ). The ophthalmologic assessment based on the Donaldson ophthalmopathy index, which combines scores awarded while evaluating five classes (soft tissues, degree of exophthalmus, oculomotor muscle status, corneal status, visual acuity) included 54 (88.5%) of 61 patients. Table 5 and 6 lists the therapeutic results obtained in patients with various degrees of exophthalmus concomitant with Graves' disease; the results are presented as the percentage of rer's recommendations and in accordance with dilution standardization of the examined serum samples, the following values of antibody levels were adopted:
<1 IU/l -negative, >2 IU/l -positive. All the patients were subjected to pre and postoperative laryngological assessment by indirect laryngoscopy; their calcium levels were determined postoperatively. Follow-up posthospitalization examinations included ophthalmologic assessment, serum calcium levels, as well as the values of antithyroid antibody TRAb, TSH and fT4.
The results described as mean values ( ) and standard deviation (s) were statistically analyzed. Intergroup differences were assessed using the t-Student test and the c 2 test.
RESULTS
All the 61 patients were treated surgically. The following procedures were performed: total thyroidectomies in 35 (57.4%) patients, the so-called Dunhill operations (total lobectomy plus subtotal resection of the contralateral side) in 14 (23%), and subtotal bilateral lobectomies in 12 (19.6%) subjects. Determinations of thyroid stimulating hormone receptor antibody TRAb levels were done preoperatively in 61 (100%) patients and postoperatively in 54 TX -total thyroidectomy; Dunhill procedure -total lobectomy plus subtotal resection of the contralateral side; STR -subtotal bilateral thyroid lobe resection 
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Total thyroidectomy in treatment of Graves' ophthalmopathy ocular disease resolution based on the pre and postoperative ophthalmopathy index and in relation to the extent of thyroidectomy. The value of the index changed in the entire investigated group, what was manifested in a statistically significant decrease in the ophthalmopathy index from 6.1±2.32 prior to treatment to 3.31±2.09 after the surgery (p<0.001, test t).
Postoperative complications as dependent on the extent of surgery are presented in tab. 7.
Deterioration of the general ocular status as confirmed by the initial ophthalmopathy index was confirmed by ophthalmology in five patients. Subjective complaints of deteriorated vision were reported by three patients (tab. 8).
DISCUSSION
To date, the selection of an optimum therapeutic modality in thyroid conditions and ocu- lar disease developing in the course of active Graves' disease remains a highly controversial issue (12). The disease process involving the orbital tissues may remain stable and unchanged or become aggressive, in extreme cases leading to loss of vision. Such a progressive form of thyroid ophthalmopathy is seen in 5-10% of patients.
Recently, numerous reports on hyperthyroidism management have been published. At present, the standard rule consists of combined therapy employing thyreostatic medications, with their inhibitory effect on thyroid peroxidase and immunosuppressive effect on population and reactivity of Th lymphocytes and thus a decrease in the synthesis of antireceptor TSH-R antibodies, in conjunction with radioiodine ablation combined with corticosteroids (13, 14, 15) .
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Total thyroidectomy in treatment of Graves' ophthalmopathy TX -total thyroidectomy; Dunhill procedure -total lobectomy plus subtotal resection of the contralateral side; STR -subtotal bilateral thyroid lobe resection, * statistically non-significant, nkw -recurrent laryngeal nerve Unfortunately, a large body of reports has been also published, which describe negative effects of 131 I therapy. Explaining this phenomenon is not easy. Various mechanisms have been implicated to play a role here. Firstly, intensification of autoimmune processes occurs in response to antigens from the destroyed thyroid gland entering the circulation. Progression of ocular disease is more frequently observed in patients, in whom radioiodine therapy has been employed several times as compared to groups, where ablation was achieved after a single radioisotope administration. In turn, uncontrolled hypothyroidism after the procedure might intensify ophthalmopathy through the mechanism of TSH receptors stimulation via increased thyreotropin levels (16) (17) (18) (19) .
Therefore, numerous centers worldwide have adopted a view that the negative effect of radioiodine therapy is decreased through administration of medium dose steroids to patients with severe ocular disease throughout the period of close post-ablation monitoring of TSH levels (10, 11, 20, 21, 22) .
In view of the above publications, the present authors have attempted to address the question on the place of thyroidectomy in managing Graves' disease with concomitant ocular symptoms. The key role in development of any autoimmune disease, including also Graves' disease, is played by antigen-presenting cells. In the thyroid gland, both thyreocytes and stroma cells fulfill this function. HLA-DR positive cells stimulate autoreactive T lymphocytes, forming -together with B lymphocytes -specific reactive centers termed the "thyroid associated lymphoid tissue" (TALT). Thus, T lymphocytes are responsible for the autoimmune process; they recognize an antigen located both in the thyroid and in the orbital tissues. Stimulation, occurring via TRAb, leads in consequence to thyroid enlargement and stimulation of extraocular muscle fibroblasts, and by the same token, development of ocular symptoms in the course of thyroid disease (23) .
In the presented series, in as many as 56 (91.8%) patients, preoperative TRAb levels were elevated. After the procedure, in 35 (57.4%) patients, TRAb values normalized, and the highest drop in the level of circulating antibodies was observed in the group of patients subjected to total thyroidectomies. In individuals, in whom remnants of thyroid tissue were left in situ (26 patients -42 .6%), ten demonstrated borderline TSH concentration values, while 12 showed a drop to normal levels. According to the literature, a high level of antireceptor TSH-R antibodies observed upon diagnosing hyperthyroidism and persisting in the course of therapy with thyreostatics and radioiodine indicates a need for selecting another, more radical treatment modality (24, 25, 26) .
Following the above assumption and supporting our opinion by the present material, total thyroidectomy seems to be the method of choice in treating Graves' disease patients, especially in individuals with high TRAb levels and concomitant compression symptoms. According to the literature, a decrease in TRAb level is significant in the majority of surgically managed patients; however, there is no unequivocal correlation between the extent of surgery and the antibody titter. In turn, when comparing the present material to data from the literature, the authors have not found recurrent hyperthyroidism, irrespectively of the surgical management method employed (8, 27) . It is a well-known fact than a postoperative increase of the antibody titter is an unfavorable prognostic sign of recurrent hyperthyroidism. Such an increase may be dictated by leaving remnants of immunogenically active glandular tissue, which again becomes an inducer and at the same time an effector of the autoimmune process, both for the thyroid tissue (recurrent goiter) and for the orbital tissues (increased exophthalmus) (28, 29) .
As it has been mentioned before, the infiltrative process in the orbital tissues may remain stable and unchanged or may increase in intensity in consequence of the effect of various factors. Hyperthyroidism recurrence following thyreostatic treatment, ineffective radioiodine treatment, a large goiter presenting with compression symptoms and concomitant high levels of antireceptor antibodies point to the surgical method of treating Graves' disease. In the present material, the predominant indication for surgery was thyroid enlargement in 57 patients (93.4%), including giant goiters in 13 individuals, as well as recurrent hyperthyroidism following pharmacotherapy in 19 patients. Clinical thyroid orbitopathy was observed in 50 patients (82%). Excision of the thyroid tissue allowed for improvement of the ocular status, which was expressed as a statistically significant decrease of the ophthalmopathy index in the entire investigated group, from 6.11 prior to treatment to 3.31 after the operation (p<0.001, test t). A particularly strong effect was noted in the group of patients subjected to total thyroidectomies (the difference was statistically significant). Nevertheless, in this group, four patients also demonstrated deterioration of their ocular status. In their randomized study, Witte et al. did not find any statistically significant differences in thyroid ophthalmopathy regression in relation to the extent of surgery. In turn, the report by Wins et al. described deterioration of the ocular status in patients, who underwent subtotal thyroidectomies (8, 27) .
Regardless of the above-presented data, thyroid dysfunctions may significantly affect the ocular status. The reason is that -irrespectively of the hyperthyroid or hypothyroid phase -the TSH receptor becomes activated, what increases surface antigen expression and sti-mulates autoimmune reactions. In hyperthyroidism, this occurs through stimulation with antireceptor antibodies (anti-TSHR), while in hypothyroidism through the thyreotropic effect of TSH itself. In the randomized study by Tallstedti, as well as in the reports of Aizawa, Marcocci, and Bartalena L, progression of ophthalmopathy was noted both in patients after thyroid surgery (16%) and after radioiodine treatment (33%) in individuals, in whom no routine steroid hormone therapy and postoperative hormonal substitution with thyroxin had been employed (16, 21, 30, 31, 32) . In the present study, no correlation was observed between the TRAb antibody levels and the intensity of ocular disease. Similar results were obtained by Witte et al. (8) .
Postoperative complications included bilateral transient recurrent laryngeal nerve palsy in one patient (1.65%). Unilateral transient palsy was seen in five patients (8.2%). Hypocalcemia was observed in four individuals (6.56%), and reoperation-requiring bleeding in one female (1.65%). Our data are convergent with data reported by the literature. In our material, both recurrent laryngeal nerve palsy and postoperative hypothyroidism were transient and the number of such cases did not differ from the literature (33) (34) (35) (36) .
Summing up, it should be stated that from the viewpoint of the patient, the most important objective of all modalities employed in treatment of Graves' ophthalmopathy, including surgical treatment, is prevention of disease remissions. Such a standpoint renders surgery a therapeutic modality alternative to radioiodine therapy, and when the patient presents with local compression symptoms, surgery becomes the method of choice. The presence of high TSHr antibody levels with concomitant ophthalmopathy suggests the risk of recurrent disease and at the same time indicates the selection of a radical therapeutic method.
In the opinion of the present authors, total thyroidectomy combined with symptomatic steroid therapy in active thyroid ophthalmopathy and followed by strict monitoring of postoperative TSH levels is a safe and effective method of hyperthyroidism treatment in patients with Graves' disease.
While performed by an experienced endocrine surgeon, total thyroidectomy is associated with a low percentage of postoperative complications.
